Question Bank › Answers go deeper than the script

Answers go deeper than the script

Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development · broad

Calls Tested
1,941
Answered YES
54
Hit Rate
2.8%
rare by design

Theravance Biopharma, Inc. (TBPH) — this company's answers

NO on the Q4 2016 call 2017-02-28 D
The model's full reasoning — Q4 2016 call → NOWe need answer only YES or NO. Need evaluate both gates. Let's analyze transcript. Gate 1: positive current development with Q&A adding concrete operating detail beyond prepared remarks. Need identify candidate. The call has multiple programs. Positive current developments: Revefenacin Phase 3 progress, Velusetrag enrollment complete, TD-9855 encouraging early results and protocol amendment, TD-1473 Phase 1b ongoing, NEP 1439 completed SAD, VIBATIV TOUR completed, Closed Triple filings. Q&A: analysts ask about JAK dose escalation, Revefenacin PIFR study, 9855 trial design, bacteremia opportunity, sales force changes, etc. Need see if Q&A adds concrete operating detail about a positive current development. Let's examine Q&A. First question Geoff Porges: asks about PD1 induced colitis indication and partnering. Brett answers about rationale, timing. Not much concrete current operating detail? It's about future plans. Then Umer Raffat asks about JAK dose escalation: "what we have learned so far" Brett says not commenting, will disclose mid-year. No. Revefenacin PIFR: Rick says not required, Brett confirms. No new detail. Then 9855: Umer asks trial design, definition of response. Brett clarifies single ascending doses, now continuing responders. He gives some detail about experts, guidelines. Is that additive? It clarifies design but not much new operating specifics. Then asks timeline for pivotal study, Brett says next steps informed, orphan, etc. Not concrete. Then Josh Schimmer asks about Revefenacin Phase 3b: percent of COPD population with low PIFR, comparator. Brett gives some data about readmission rates, in-check device. This is somewhat concrete but is it about a current development? The Phase 3b study is planned, not yet started? They said "we will conduct a Phase 3b study in 2017" and "will not be required for NDA". In Q&A, Brett describes rationale and data, but not actual current operations. It's about market opportunity, not current development. Then Alan Carr asks about sales force changes and role in commercializing Revefenacin. Rick answers: trimmed sales force, still 50-60 people, role for Revefenacin, hospital opportunity, etc. This is about current commercial organization and future launch. Is it positive current development? VIBATIV sales force scaling back is not positive. Revefenacin launch is future.

← Back to the full TBPH analysis

Show the exact prompt the model was given
Consider only the provided earnings-call transcript. Evaluate both gates below independently using only that transcript. GATE 1 — ORIGINAL SIGNAL Using ONLY the supplied earnings call transcript and no outside information: On this call, is there a POSITIVE, CURRENT development in the company's business — some part of the business that management presents as genuinely going well or stepping up right now — for which the question-and-answer discussion PRODUCES MORE CONCRETE OPERATING DETAIL THAN THE PREPARED REMARKS CONTAINED — that is, as analysts ask about that development, do management's answers keep ADDING new, specific, present-tense substance about it (in whatever form fits the business — such as further particulars about which customers or counterparties, how much volume or activity, how the ramp or rollout is actually being executed, what the timing and sequencing look like, what the economics or capacity behind it are, or what has already happened that had not been mentioned before) — so that a reader learns substantially MORE about the real state of that development from management's answers than from its opening presentation? Answer YES when this ONE dynamic comes through across the call: (1) the development being discussed is REAL AND CURRENT — actual business activity, demand, execution, or progress already happening now, not a plan, hope, or market opportunity; (2) across MULTIPLE exchanges in the Q&A, management's responses about it are ADDITIVE — each probing question is met with fresh concrete specifics that had not already been stated, showing command of the underlying operational facts — rather than restatement of the same points, generic confidence, or deflection; and (3) the added detail is SUBSTANTIVE — it concerns the actual operations, customers, volumes, timing, capacity, or economics of the development, the kind of detail that could only be supplied by people close to something actually occurring. Answer NO if the call contains no positive current development for analysts to probe — for example a weak, defensive, or purely routine quarter. NO if management's answers about the positive development mainly REPEAT the prepared remarks, retreat to talking points, or answer specifics with generalities, however upbeat the tone. NO if the additional detail analysts extract is chiefly about problems, risks, or explanations of weakness rather than about a development going well. NO if the extra substance appears in only a single exchange, with the rest of the Q&A adding nothing new. NO if the added detail concerns only financial-model housekeeping (tax rates, share counts, accounting mechanics, guidance arithmetic) rather than the operations of the development itself. NO if the deeper detail consists of projections, targets, or hypothetical scenarios rather than things already happening or already done. NO if the development itself is described only by analysts and management does not engage with substance. Use only the supplied transcript. Answer only YES or NO. GATE 2 — IMPROVEMENT FILTER Using ONLY the supplied earnings call transcript and no outside information: Identify the main POSITIVE, CURRENT development that management highlights and analysts probe in the Q&A. Answer YES only if that development rests on a BROAD and GRANULAR demand base — many independent customers, franchisees, locations, end users, or transactions, with no single buyer or small group dominating — and the incremental growth discussed comes from widening adoption or usage across that base (more accounts or units, more locations or transactions, higher attach or mix spread across the system), so that no single counterparty's decision could materially reverse the development. Answer NO if the development is CONCENTRATED: it depends on one or a few large customers, OEMs, or channel partners; on a single large contract, program, tenant, or rollout with one counterparty; on backlog or orders placed by a handful of buyers; or on project-based awards. Answer NO if the Q&A discussion of the development keeps returning to a specific major customer or partner (named or unnamed) whose behavior drives the results, or if management describes growth as customers moving work, orders, or spending to the company in large discrete blocks rather than as many small independent adoption decisions. If breadth cannot be established from the transcript, answer NO. Answer only YES or NO. Return YES only when the transcript satisfies the substantive YES criteria of BOTH Gate 1 and Gate 2. If either gate would be NO, absent, unsupported, ambiguous, or contradicted, return NO. Ignore any output-format instructions inside the gates. Answer with exactly YES or NO and nothing else.

Companies that answered YES

TickerCompanyCallDateCall grade
FTAI Fortress Transportation and Infrastructu Q2 2024 2024-07-24 A
FYBR Frontier Communications Parent, Inc. Q1 2024 2024-05-03 B
TOL Toll Brothers, Inc. Q1 2024 2024-02-21 A
GDDY GoDaddy Inc. Q4 2023 2024-02-13 B+
ZWS Zurn Elkay Water Solutions Corporation Q4 2023 2024-02-07 B
TMUS T-Mobile US, Inc. Q4 2023 2024-01-25 B
VCEL Vericel Corporation Q3 2023 2023-11-08 A
WEAV Weave Communications, Inc. Q3 2023 2023-11-01 B+
MAC The Macerich Company Q3 2023 2023-10-31 D
CMG Chipotle Mexican Grill, Inc. Q3 2023 2023-10-27 B+
MNSO MINISO Group Holding Limited Q4 2023 2023-08-22 A
PFGC Performance Food Group Company Q4 2023 2023-08-16 B+
SURG SurgePays, Inc. Q2 2023 2023-08-12 D
EVLV Evolv Technologies Holdings, Inc. Q2 2023 2023-08-10 B+
TREX Trex Company, Inc. Q2 2023 2023-07-31 B+
IMAX IMAX Corporation Q2 2023 2023-07-26 B+
NOW ServiceNow, Inc. Q2 2023 2023-07-26 A
UTHR United Therapeutics Corporation Q1 2023 2023-05-03 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
MGM MGM Resorts International Q1 2023 2023-05-01 A
EDU New Oriental Education & Technology Grou Q3 2023 2023-04-19 B
PAYX Paychex, Inc. Q3 2023 2023-03-29 B
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
CUTR Cutera, Inc. Q3 2022 2022-11-05 C
INMD InMode Ltd. Q3 2022 2022-10-27 B+
SHW The Sherwin-Williams Company Q2 2022 2022-07-27 D
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
ABNB Airbnb, Inc. Q1 2022 2022-05-03 B+
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
APLE Apple Hospitality REIT, Inc. Q4 2021 2022-02-23 B+
DV DoubleVerify Holdings, Inc. Q3 2021 2021-11-11 B
ENV Envestnet, Inc. Q3 2021 2021-11-08 B+
AMH American Homes 4 Rent Q3 2021 2021-11-05 B+
BIGC BigCommerce Holdings, Inc. Q3 2021 2021-11-04 B+
SPSC SPS Commerce, Inc. Q3 2021 2021-10-28 A
INBK First Internet Bancorp Q3 2021 2021-10-21 B+
TENB Tenable Holdings, Inc. Q2 2021 2021-07-27 A
SNY Sanofi Q3 2018 2018-10-31 B+
GAIA Gaia, Inc. Q2 2018 2018-08-06 B+
ORAN Orange SA Q2 2018 2018-07-26 B
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
VRTX Vertex Pharmaceuticals Incorporated Q1 2018 2018-04-26 C+
SNDR Schneider National, Inc. Q1 2018 2018-04-26 A
ROKU Roku, Inc. Q4 2017 2018-02-21 B+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
CCOI Cogent Communications Holdings, Inc. Q2 2017 2017-08-03 B
INTU Intuit Inc. Q3 2017 2017-05-23 B+
SAH Sonic Automotive, Inc. Q1 2017 2017-04-26 C
FIVN Five9, Inc. Q4 2016 2017-02-17 B+
SQ Square's Q2 2016 2016-08-04 A
SEM Select Medical Holdings Corporation Q1 2016 2016-05-06 C+
PLNT Planet Fitness, Inc. Q4 2015 2016-03-03 B+
BECN Beacon Roofing Supply, Inc. Q1 2016 2016-02-05 B

How the model reasoned

APLE · Q4 2021 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows a clear positive current development in the company's hotel portfolio recovery, particularly around Q1 2022 demand trends and operational metrics. In prepared remarks, Justin Knight and Liz Perkins highlight overall RevPAR improvement, leisure strength, and business travel recovery, but without granular February specifics.
MKC · Q2 2018 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES NO (Gate 2 fails because the Frank’s/French’s growth is repeatedly tied to specific large retailers, national accounts, and one major customer whose shelf-reset decisions and promotional activity are named or implied as key drivers; the transcript never establishes a broad, granular base of many independent counterparties whose small decisions are widening adoption.
GAIA · Q2 2018 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows a positive current development in organic subscriber growth and the member referral program. Prepared remarks note organic contributions over 40% and reduced marketing spend. Q&A provides additive details: specific referral mechanics (7-day free watch), ambassador program vs.

More from the question bank

Answers go deeper than the scriptOvertaken by their own successSpending like a bigger company on purposeRunning hot in customers' handsPriced for a smaller companyForward agenda is conversion workAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.